纳武利尤单抗治疗晚期肾细胞癌：临床实践考量
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
作者信息
Joseph Richard W, Chatta Gurkamal, Vaishampayan Ulka
机构信息
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
Clinical Chief for Genitourinary Medicine, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY.
出版信息
Urol Oncol. 2017 Apr;35(4):142-148. doi: 10.1016/j.urolonc.2017.01.017. Epub 2017 Mar 2.
BACKGROUND
Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy.
METHODS AND PURPOSE
This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.
背景
纳武单抗是晚期肾细胞癌患者的一种重要的新治疗选择，与血管内皮生长因子靶向治疗相比，其作用机制不同。它是一种程序性死亡1免疫检查点抑制剂抗体，其反应模式、疗效和安全性与传统的抗血管生成或雷帕霉素哺乳动物靶点抑制治疗不同。
方法与目的
本述评讨论并评估了现有文献中纳武单抗的临床经验，并提出了在晚期肾细胞癌中使用纳武单抗免疫治疗以优化临床管理的实际考虑因素。
Zotero 插件